AbCellera sets November 9 date for Q3 2026 results and a 3:00 p.m. Pacific earnings call
Market Chameleon (Fri, 2-Oct 5:04 AM ET)
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Business Wire (Thu, 1-Oct 4:05 PM ET)
AbCellera Sets October 2026 Spotlight for ABCL635 Phase 2 Menopause Symptom Data
Market Chameleon (Thu, 17-Sep 3:10 AM ET)
Business Wire (Wed, 16-Sep 4:05 PM ET)
Globe Newswire (Wed, 19-Aug 8:56 AM ET)
Business Wire (Thu, 13-Aug 12:05 AM ET)
These Have the Market Hot Zone Catalysts and Setups
Globe Newswire (Tue, 11-Aug 4:52 PM ET)
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Business Wire (Tue, 11-Aug 4:01 PM ET)
ABCL Phase 2 Results Spark Renewed Interest: 83% Reduction in Vasomotor Symptoms Stands Out
Market Chameleon (Tue, 11-Aug 7:21 AM ET)
The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
Globe Newswire (Mon, 10-Aug 10:39 AM ET)
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.
As of October 8, 2026, ABCL stock price declined to $11.99 with 3,676,080 million shares trading.
ABCL has a beta of 2.63, meaning it tends to be more sensitive to market movements. ABCL has a correlation of 0.10 to the broad based SPY ETF.
ABCL has a market cap of $3.89 billion. This is considered a Mid Cap stock.
Last quarter Abcellera Biologics - Common Shares reported $4 million in Revenue and -$.18 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.01.
In the last 3 years, ABCL traded as high as $15.02 and as low as $1.89.
The top ETF exchange traded funds that ABCL belongs to (by Net Assets): IBB, IDNA, SPDW, ONEQ, AVUS.
ABCL has outperformed the market in the last year with a return of +107.8%, while the SPY ETF gained +17.0%. In the last 3 month period, ABCL beat the market returning +55.9%, while SPY returned +4.0%. However, in the most recent 2 weeks ABCL has underperformed the stock market by returning -2.6%, while SPY returned +1.0%.
ABCL support price is $12.26 and resistance is $13.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL shares will trade within this expected range on the day.
